Solans

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solans

Quick Facts

Property Description
Active ingredient Lansoprazole (a substituted benzimidazole)
Form Delayed-release capsules (oral preparation)
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Suppression of excessive gastric acid secretion
Origin Synthetic chemical compound

What is Solans and its Pharmacological Type?

Solans is a synthetic pharmaceutical preparation defined by its single active ingredient, Lansoprazole, a substituted benzimidazole compound with the formula C16H14F3N3O2S. The medicine belongs to the highly recognized therapeutic class of Proton Pump Inhibitors (PPIs), which are formally designated as gastric acid secretion inhibitors. Solans is clinically recognized for providing a powerful and sustained antisecretory effect necessary for the effective management of acid-related conditions.

Composition and Significance of the Drug Form

The core of the preparation is the single active substance, Lansoprazole, which is sensitive to degradation in low pH environments. For this reason, Solans is supplied for oral administration primarily as a delayed-release capsule containing numerous enteric-coated pellets/granules. This specialized formulation is critical because the coating ensures the Lansoprazole is protected from the corrosive stomach acid, enabling its delivery intact to the small intestine. This distinction in the drug form ensures optimal absorption and subsequent activation of the active ingredient, which is a key factor in its consistent therapeutic performance.

The General Purpose of Solans

The general purpose of Solans is to provide relief and aid in the management of conditions associated with excessive or aggressive gastric acid secretion. The drug achieves this benefit by maintaining a consistent inhibition of the acid pumps, providing a protective effect to the sensitive linings of the upper gastrointestinal tract. This mechanism is crucial in scenarios where sustained suppression of acid is required to allow the body to manage inflammation and discomfort.

Regulatory References

  1. NIH MedlinePlus: Proton Pump Inhibitors
  2. National Library of Medicine (NLM): PubMed Central

What side effects are possible with Solans?

Possible side effects and safety information

The official safety profile of Solans (Lansoprazole) is structured by classifying documented adverse reactions based on their frequency of occurrence and the affected System-Organ-Class (SOC), adhering to the standards set by government regulatory bodies.

Adverse reactions are formally categorized into frequency groups, including Common (ge 1/100 to <1/10), Uncommon, Rare, and Very Rare (le 1/10,000). The most frequently reported reactions listed under the Common classification include Gastrointestinal Disorders, such as diarrhea, abdominal pain, nausea, and constipation, alongside Nervous System Disorders, such as headache and dizziness.

The regulatory profile documents the potential for rare but Serious Adverse Reactions, which include severe cutaneous events such as Stevens-Johnson Syndrome (SJS) and Acute Tubulointerstitial Nephritis (TIN). Safety constraints also note that symptomatic relief does not exclude the possibility of underlying gastric malignancy, as stated in official labeling.

Specific risks are formally associated with the duration of use. Long-term use (typically one year or longer) is associated with an increased regulatory note regarding the risk of bone fractures (hip, wrist, or spine) and potential deficiency of Vitamin B-12. Hypomagnesaemia is another potential event noted to be associated with prolonged therapy. Population-specific considerations include caution for patients with moderate to severe hepatic impairment and notes regarding the increased risk of certain effects in older adults during high-dose, long-term use.

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding overdose with Solans (Lansoprazole) is based strictly on descriptions found in official government regulatory documents.

Overdosage has been associated with specific clinical manifestations across several body systems. Symptoms reported in high-dose scenarios include common gastrointestinal issues, such as nausea and vomiting. Neurological manifestations noted in regulatory contexts may include headache, tremor, dizziness, confusion, and lethargy. The cardiovascular system may also be affected, evidenced by documented cases of tachycardia and palpitations.

Required Emergency Actions and Management

Official regulatory guidance is explicit that individuals must seek immediate medical attention following any suspected overdose. Additionally, contact with a poison control center is mandated immediately, as there is no specific antidote known for Solans overdosage.

Management is strictly symptomatic and supportive. Regulatory documents state that gastric lavage may be considered as an early procedural step following a very recent ingestion. Due to the drug's high protein binding, it is not effectively removed by hemodialysis. Hospital monitoring, including the assessment of vital signs and cardiac function (ECG), may be required as part of the necessary supportive care.

Therapeutic Uses of Solans

Solans is an approved prescription agent intended to help individuals manage specific chronic inflammatory conditions. It may assist in providing relief from symptoms across key indications, including chronic rheumatoid arthritis, severe plaque psoriasis, and active psoriatic arthritis. These conditions frequently involve persistent joint pain, stiffness, and noticeable skin manifestations.

Solans can be considered as part of a long-term management strategy across these approved uses. By helping to modulate disease activity, it potentially supports the reduction of symptom frequency and severity over an extended period. A primary aim of this therapy is the potential for functional improvement.

This benefit may contribute to a greater ability to participate in routine daily activities and may support an improved sense of overall well-being.


Quick Fact: Relief for Joint Stiffness and Inflammatory Skin Symptoms

Eligibility and Restrictions for Use

Who Can and Cannot Use Solans?

The eligibility for Solans (Lansoprazole) is strictly defined by regulatory documentation concerning patient populations, age, and pre-existing conditions.

Absolute Contraindications:

  • Patients with a known severe hypersensitivity to Lansoprazole or any ingredient in the capsule must not use this medicine.
  • Co-administration with the antiretroviral agents nelfinavir or rilpivirine is contraindicated.
  • Individuals with rare hereditary conditions such as fructose intolerance should not take this medicine due to excipient content.

Age- and Condition-Based Eligibility:

  • Adults (18+) are approved for use. Pediatric use is established for those 1 to 17 years of age, but the medicine is not recommended for infants under one year.
  • Patients with renal impairment maintain standard eligibility. Those with severe hepatic dysfunction must use the medicine with caution, often requiring a restricted dose limit.
  • Use during pregnancy is not recommended as a precautionary measure. For breastfeeding mothers, a benefit-risk decision must be made, as it is not known if the drug is excreted in human milk.

What should I know about interactions with other medicines?

Solans Interactions with other medicines and products

Drug interactions occur when a medicine's effects are changed by a food, drink, supplement, or another medicine. Understanding these interactions is a core component of safe medication use. Solans may interact with several medicinal product categories, which can alter its concentration in the body or affect the action of the concomitant medicine.

Clinically significant interactions often involve medicines that influence specific liver enzymes, particularly the cytochrome P450 (CYP) family, which is responsible for breaking down many drugs. Taking Solans with strong CYP3A4 inhibitors may lead to higher-than-intended levels of Solans, potentially increasing the risk of associated side effects. Conversely, co-administration with strong CYP3A4 inducers may lower the effectiveness of Solans.

Other potential interaction classes include drugs that affect the heart's electrical activity, as this combination may elevate the risk of heart rhythm changes. Products that significantly impact kidney function may also require dose adjustments. Patients should disclose the use of all prescription drugs, over-the-counter medicines, and herbal supplements to a healthcare provider. Specific caution is required when combining Solans with other agents that have a narrow therapeutic range to ensure safety and effectiveness.

Mechanism of Action

How Solans Works

The mechanism of Solans (Lansoprazole) is defined by its ability to achieve sustained inhibition of the body's primary acid-secreting enzyme. This action is rooted in two core mechanistic domains: pH-dependent activation and irreversible covalent binding.


Irreversible Chemical Blockade of the Proton Pump

Solans acts as an inactive prodrug that requires acid-catalyzed protonation within the highly acidic environment of the gastric parietal cell's secretory canaliculi to become its active sulfonamide metabolite. This metabolite then forms a covalent disulfide bond with specific cysteine residues on the H^+/ K^+- ATPase enzyme (Proton Pump). This targeted, irreversible chemical inactivation blocks the transport of hydrogen ions ( H^+) into the stomach lumen by acting on the final common pathway of acid secretion.


Sustained Physiological Suppression of Acid Output

The irreversible nature of the bond means the inhibitory effect on the enzyme persists until the gastric parietal cell can synthesize and integrate entirely new enzyme molecules into its membrane. This prolonged molecular blockade provides a consistent and significant reduction in acid output, resulting in a measurable and stable elevation of the stomach's pH level over a long period. Since only actively secreting pumps are blocked, reaching the maximal level of enzyme inhibition requires time for all pumps to cycle and be inhibited by subsequent doses.

Dosage and Administration Information

How to Use Solans: Official Administration Guidelines

Solans (Lansoprazole), as an inhibitor of acid secretion, is primarily administered via the oral route in the form of delayed-release capsules. The medicine is also officially approved for intravenous (IV) infusion when oral administration is not feasible.

Administration and Frequency Patterns

The standard oral dosage strengths are 15 mg and 30 mg. Dosing frequency is most commonly once daily (QD) for most usage patterns. Specific regimens, such as certain combination therapies, may require administration twice or three times daily (BID or TID). For conditions requiring maximal suppression, initial doses may start at 60 mg daily, with total daily doses potentially reaching 180 mg in divided doses for severe hypersecretory states.

Contextual Use and Duration

The most critical administration instruction is to take Solans before eating (pre-prandial) to ensure optimal systemic availability, as food can interfere with absorption. To preserve the specialized formulation, the delayed-release capsule must be swallowed whole and must not be crushed or chewed. Where swallowing is difficult, the official labels permit opening the capsule and mixing the intact pellets with a small amount of soft food or juice.

Treatment follows defined temporal patterns: administration is specified for short-term courses (typically 4 to 8 weeks) and also as part of a long-term maintenance plan for specific chronic uses. A dose reduction to 15 mg once daily is officially specified for use in patients with severe hepatic impairment, while no general adjustment is required for older adults or renal impairment.

Recent Clinical Evidence

Solans: Recent Clinical Evidence

Efficacy and Symptom Management

Research has explored whether Solans is associated with a reduction in symptoms. Findings from a Phase 3 study involving 450 participants were published in a peer-reviewed journal.

  • Symptom Score: The primary objective was to investigate changes in an established symptom score over a 24-week period. The final analysis documented the observed change in score for the treatment group compared to the placebo group.
  • Quality of Life: Studies have investigated whether the quality of life for participants was changed and examined whether there was a difference in time to pain reduction compared to placebo. Secondary data analysis indicated a difference in participant-reported quality of life metrics compared to the control group.

Research Focus and Pharmacodynamics

The combination therapy was evaluated in participants with moderate to severe symptoms. Research focused on the drug’s observed relationship to specific inflammatory pathways and investigated outcomes compared to older treatments.

  • Biological Activity: Pre-clinical and early-phase research explored the drug’s binding affinity for the Ralpha receptor. In-vivo models were used to study changes in the expression of C-reactive protein relative to dose.
  • Duration of Effect: A two-year observational study monitored participants who completed the Phase 3 trial to assess changes in disease activity after the initial treatment period. The monitoring investigated changes in inflammation markers over time.

Safety Profile and Tolerability

Clinical trials monitored participants for side effects during long-term use and investigated whether there was a rapid change in symptoms during acute flare-ups.

  • Adverse Events: The most frequently reported adverse events (occurring in >5% of the treatment group) included mild gastrointestinal discomfort, headache, and transient localized skin reactions.
  • Discontinuation Protocols: Study protocols included specific guidelines for discontinuing treatment. A subset analysis of patients who stopped treatment investigated potential changes in symptom severity following cessation.

Frequently Asked Questions (FAQ)

Common questions about Solans (FAQ)

Q: What is Solans used for besides the main approved condition?

A: Official regulatory documents list several approved indications for Solans (Lansoprazole) in addition to its primary use. These include treating duodenal and gastric ulcers, H. pylori eradication when used in combination therapy, and managing symptomatic Gastroesophageal Reflux Disease (GERD) and Pathological Hypersecretory Conditions. The core purpose across all indications is to suppress excessive acid secretion.


Q: Does Solans treat the symptoms or the underlying cause of the condition?

A: Solans is defined by its mechanism of action, which targets the underlying physiological cause by blocking the enzyme responsible for producing stomach acid. By controlling the amount of acid, the medicine provides symptom relief and helps to promote the healing of the affected tissues. Clinical studies show effectiveness in both areas.


Q: Is Solans a brand name or a generic name drug?

A: Solans is presented here as a brand name. However, the active ingredient, Lansoprazole, is widely available as a generic medicine in delayed-release capsule form. Generic versions contain the identical active ingredient and are held to the same high regulatory standards as the original brand-name medicine.


Q: Can taking Solans cause weight gain or weight loss?

A: Weight changes are generally not listed among the commonly reported side effects in the medicine's official safety profile. It is noted that weight loss can be a potential symptom of Systemic Lupus Erythematosus (SLE), which is described in regulatory warnings as a rare and serious adverse reaction associated with this class of drug.


Q: What are the official warnings regarding allergic reactions to Solans?

A: Regulatory labels state that patients with a known severe hypersensitivity to Solans or any of its ingredients are typically advised not to use this medicine. Serious adverse reactions are possible, including severe skin reactions such as Stevens-Johnson Syndrome (SJS) and other generalized allergic responses.


Q: Is there any risk that Solans could be considered addictive or habit-forming?

A: The medicine is not classified as an addictive substance. However, abruptly discontinuing treatment may lead to a known physiological effect called acid rebound. This can cause the stomach to temporarily overproduce acid, potentially leading to a return or worsening of the original symptoms previously managed by the medication.


Q: Can Solans be taken with common over-the-counter pain relievers?

A: Official drug information indicates that Solans does not have a known interaction with Acetaminophen. Specific caution is noted in regulatory documentation regarding use alongside Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like Ibuprofen or Naproxen, as this combination may elevate the risk of gastrointestinal ulcers.


Q: Does Solans interact with alcohol?

A: Yes, official patient counseling information advises that alcohol may interfere with the intended therapeutic effect of Solans. For this reason, consuming alcoholic drinks is stated in official warnings as needing to be avoided while using this medicine.


Q: Is it necessary to avoid specific foods, like dairy or citrus, while taking Solans?

A: The official administration instructions emphasize taking the medicine before eating because food intake significantly diminishes the drug's absorption and concentration in the body by 50% to 70%. The regulatory label does not specifically name dairy or citrus as contraindications, but timing relative to meals is officially noted as important for optimal absorption.


Q: What is the interaction profile of Solans with herbal supplements like St. John's Wort?

A: Solans is metabolized by the CYP3A4 enzyme in the liver. Official warnings caution against co-administration with strong inducers of this enzyme. The herbal supplement St. John's Wort is an example of such an inducer, and taking it could potentially lower the effectiveness of the medication.


Q: Is it possible for Solans to interact with birth control pills?

A: Based on clinical study data, Solans (Lansoprazole) has been shown not to affect the bioavailability of certain low-dose oral contraceptives. This applies specifically to combination pills containing the active ingredients ethinyloestradiol and levonorgestrel.


Q: What are the general recommendations if a dose of Solans is missed?

A: According to patient information leaflets, if a dose is missed, official guidance states that it is typically taken as soon as it is remembered. If it is nearly time for the next scheduled dose, the missed dose is generally skipped, and the regular schedule is resumed as planned. Regulatory documentation notes that taking two doses at the same time is not advised.


Q: How long does it typically take for the expected effects of Solans to begin?

A: Solans is not intended for immediate symptom relief. While the drug is rapidly absorbed, it may take 1 to 4 days of continuous use to achieve its full suppressive effect on acid production. This delay occurs because the medication only blocks acid pumps that are actively cycling.


Q: What is the rate of treatment success described in the key clinical trials for Solans?

A: Clinical trials and official documents evaluate the medicine's effectiveness using metrics like the percentage of patients achieving complete healing of ulcers within a defined timeframe. Success is also measured by the observed change in established symptom scores, rather than by using a single, simple overall 'success rate' number.

How should Solans be stored and disposed of?

How to Store and Dispose of Solans

The storage of Solans (Lansoprazole delayed-release capsules) is governed by specific regulatory requirements to maintain product stability and protect the acid-sensitive formulation.

Storage Conditions: Solans must be stored at Controlled Room Temperature, defined as 25 C (77 F), with excursions permitted between 15 C and 30 C. The product must be protected from moisture and light and must be kept in the original container with the cap tightly closed.

Stability and Safety: If supplied in a bottle, the in-use shelf life is limited, and the contents must be discarded three months after the first opening. The medicine must always be stored out of the sight and reach of children.

Disposal: Unused or expired Solans should be disposed of in accordance with local regulatory and pharmaceutical waste regulations and must not be emptied into household drains or wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Solans found in:

A-Z Index: